NCT05664932进行中（未招募）3 期
Evaluate the Immunogenicity and Safety of a Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Above Who Have Completed Two-dose or Three-dose Inactivated COVID-19 Vaccine
Guangzhou Patronus Biotech Co., Ltd.1 个研究点 分布在 1 个国家目标入组 1,200 人开始时间: 2022年12月28日最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,200
- 试验地点
- 1
- 主要终点
- Geometric neutralizing titers (GMT) of neutralizing antibody against variants of concern(VOCs)
研究概览
简要总结
A total of 1200 people aged 18 years and older who have completed two or three-dose inactivated COVID-19 vaccine for 6-18 months will be recruited in this study. Subjects will be received 1 dose at day 0 as a booster vaccination.Immunogenicity and safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 will be evaluated.
详细描述
The study is a randomized, double-blind, positive control design and 1200 subjects are randomly assigned to LYB001 and positive control groups in a 1:1 ratio to evaluate the safety and immunogenicity as a booster vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects aged 18 years and older, including both males and females;
- •Subjects who agree to participate in this clinical trial voluntarily and sign the informed consent form, are capable of providing valid identification, understanding and complying with the requirements of the clinical protocol.
- •Subjects who have been vaccinated with two-dose or three-dose inactivated COVID-19 vaccine for 6-18 months .
- •For female participants of childbearing potential, effective contraception measures should be used within 2 weeks prior to participation in this study and the results of pregnancy test is required to be negative. Participants should voluntarily agree to use effective contraceptive measures from the time of signing the informed consent form to the end of the study (effective contraceptive measures including oral contraceptives (excluding emergency contraceptives), injectable or implantable contraceptives, sustained-release topical contraceptives, hormonal patches, intrauterine device, sterilization, abstinence, condoms (for males), diaphragms, cervical caps, etc.).
排除标准
- •Receipt of any COVID-19 prophylactic medication other than inactivated COVID-19 vaccine (e.g., receipt history of any approved or under developing COVID-19 vaccines, or other COVID-19 prophylactic medication, etc.), or previous vaccination history other than two- or three-dose inactivated COVID-19 vaccination;
- •Systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg or axillary body temperature ≥ 37.3°C prior to enrolment;
- •Known allergy, or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients;
- •History of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS);
- •History of COVID-19, or close contact with a confirmed/suspected COVID-19 patient or positive results for SARS-CoV-2 nucleic acid ;
- •Receipt of any live attenuated vaccine within 28 days prior to vaccination, and other vaccines such as subunit and inactivated vaccine within 14 days prior to vaccination;
- •Receipt of blood or blood-related products, including immunoglobulins, monoclonal antibodies, within 3 months prior to vaccination; or any planned use during the study period.
- •Subjects with the following diseases:
- •Any acute diseases or acute attacks of chronic diseases within 7 days prior to enrolment；
- •Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.；
- •Congenital or acquired immunodeficiency or autoimmune disease, or long-term receipt (>14 consecutive days) of glucocorticoid (reference value for dose: ≥20 mg/day prednisone or equivalent) or other immunosuppressive agents within the past 6 months, with exception of inhaled or topical steroids, or short-term use (≤14 consecutive days) of oral corticosteroids；
- •Currently suffering from or diagnosed with infectious diseases, such as hepatitis B, hepatitis C, syphilis, AIDS etc.；
- •History or family history of neurological disorders (convulsions, epilepsy, encephalopathy, etc.) or psychiatric disorders；
- •Asplenia, or functional asplenia；
- •Presence of severe, uncontrollable or hospitalized cardiovascular diseases, endocrine diseases, blood and lymphatic diseases, immune diseases, liver and kidney diseases, respiratory diseases, metabolic and skeletal diseases, or malignant tumors;
- •Contraindications to IM injections and blood draws, such as coagulation disorders, thrombotic or bleeding disorders, or conditions that needs continuous anticoagulant usage.
- •Drug or alcohol abuse (alcohol intake ≥ 14 units per week) which in the investigator's opinion would compromise the participant's safety or compliance with the study procedures;
- •Pregnant or lactating females;
- •Having participated or participating in COVID-19 related clinical trials, and those participating or planning to participate in other clinical trials during the study period;
- •Presence of any underlying disease or condition which, in the opinion of the investigator, may place the subject at unacceptable risk, is unable to meet the requirements of the protocol, or interfere with the assessment of vaccine response
研究组 & 干预措施
LYB001 Booster Group
Experimental
Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive 30μg LYB001 at day 0 as a booster vaccination.
干预措施: Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 (Biological)
ZF2001 Booster Group
Active Comparator
Subjects 18 years of age or older who has completed two or three-dose inactivated COVID-19 will receive ZF2001 at day 0 as a booster vaccination.
干预措施: ZF2001 (Biological)
结局指标
主要结局
Geometric neutralizing titers (GMT) of neutralizing antibody against variants of concern(VOCs)
时间窗: Day 14 after booster vaccination
Geometric neutralizing titers (GMT) of neutralizing antibody against variants of concern(VOCs) at day 14 after booster vaccination in cohort 1.
次要结局
- Seroconversion rate of neutralizing antibody against SARS-CoV-2 wild strain and variants of concern(VOCs).(Day 14 ,day 28 ,month 6 after vaccination)
- Geometric neutralizing titers (GMT) of neutralizing antibody against SARS-CoV-2 wild strain(Day 14 ,day 28 ,month 6 after vaccination)
- The occurrence of adverse events(30 mins,7 days and 28 days after vaccination)
- GMT of binding antibody against SARS-CoV-2 S protein(Day 14 ,day 28 ,month 6 after vaccination)
- Seroconversion rate of binding antibody against SARS-CoV-2 S protein(Day 14 ,day 28 ,month 6 after vaccination)
- The occurrence rate of serious adverse events (SAEs) and adverse events of special interest (AESIs)(Day 0 to 12 months after vaccination)
- Geometric mean fold rise(GMFR) of binding antibody against SARS-CoV-2 S protein(Day 14 ,day 28 ,month 6 after vaccination)
- Geometric mean fold rise(GMFR) of neutralizing antibody against SARS-CoV-2 wild strain and variants of concern(VOCs)(Day 14 ,day 28 ,month 6 after vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of IVX-A12 in Adults ParticipantsHealthy ParticipantsNCT06481579Icosavax, Inc.143
Unknown
4 期
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV InfectedCOVID-19HIV InfectionsNCT05075044China National Biotec Group Company Limited400
已完成
不适用
Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in IndonesiaSafety IssuesNCT05037227PT Bio Farma1,100
已完成
1 期
Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19COVID-19SARS-CoV-2NCT05233826Codagenix, Inc20
已完成
2 期
Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly SubjectsSeasonal InfluenzaNCT01151059Novartis Vaccines138